{"protocolSection":{"identificationModule":{"nctId":"NCT00269152","orgStudyIdInfo":{"id":"10105"},"secondaryIdInfos":[{"id":"H3E-SB-S089","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer","officialTitle":"A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2005-12"},"primaryCompletionDateStruct":{"date":"2007-11","type":"ACTUAL"},"completionDateStruct":{"date":"2013-07","type":"ACTUAL"},"studyFirstSubmitDate":"2005-12-21","studyFirstSubmitQcDate":"2005-12-21","studyFirstPostDateStruct":{"date":"2005-12-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2008-11-12","resultsFirstSubmitQcDate":"2009-04-22","resultsFirstPostDateStruct":{"date":"2009-06-11","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-28","lastUpdatePostDateStruct":{"date":"2015-08-18","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in participants with completely resected, stage Ib or IIa/IIb non-small cell lung cancer (NSCLC).\n\nA two-stage design will be employed independently for both treatment arms, with the possibility of stopping each treatment early for lack of feasibility."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":122,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"A: Pemetrexed + Cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: pemetrexed","Drug: cisplatin"]},{"label":"B: Pemetrexed + Carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: pemetrexed","Drug: carboplatin"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 4 cycles","armGroupLabels":["A: Pemetrexed + Cisplatin","B: Pemetrexed + Carboplatin"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"cisplatin","description":"75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles","armGroupLabels":["A: Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"carboplatin","description":"area under the curve (AUC) 5 milligrams per milliliter\\*minute (mg/ml\\*min), intravenous (IV), every 21 days x 4 cycles","armGroupLabels":["B: Pemetrexed + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The Feasibility of Post-Surgery Chemotherapy","description":"Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \\>=Grade 3 at 30 days after last infusion.","timeFrame":"every 21-day cycle for 4 cycles up to 30 days after last infusion"}],"secondaryOutcomes":[{"measure":"Grade III/IV Adverse Events","description":"Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.","timeFrame":"every 21-day cycle for 4 cycles"},{"measure":"Overall Survival at 3 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.","timeFrame":"baseline to date of death from any cause, assessed at 3 years"},{"measure":"3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.","timeFrame":"length of time disease free, assessed at 3 years"},{"measure":"Overall Survival at 6 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.","timeFrame":"Baseline to date of death from any cause assessed at 6 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically proven non-small cell lung cancer stage Ib, IIa or IIb\n* Must have complete tumor resection by pneumonectomy or lobectomy\n* Must have been surgically proven to be N2 negative\n\nExclusion Criteria:\n\n* Serious concomitant systemic disorder\n* Post-operative complications or other surgery related conditions\n* A prior malignancy other than NSCLC unless that malignancy was diagnosed and treated at least 5 years ago","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_CHAIR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75571","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rennes","zip":"35033","country":"France","geoPoint":{"lat":48.11109,"lon":-1.67431}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Saint-Priest-en-Jarez","zip":"42270","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bielefeld","zip":"D-33604","country":"Germany","geoPoint":{"lat":52.03333,"lon":8.53333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cologne","zip":"D-51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Großhansdorf","zip":"D-22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Halle","zip":"D-06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hanover","zip":"D-30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kassel","zip":"34125","country":"Germany","geoPoint":{"lat":51.31667,"lon":9.5}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mainz","zip":"D-55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Santiago de Compostela","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"FG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 milligrams per milliliter\\*minute (mg/ml\\*min), intravenous (IV), every 21 days x 4 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"One participant in Pemetrexed+Carboplatin actually received Pemetrexed+Cisplatin","numSubjects":"63"},{"groupId":"FG001","comment":"4 were randomized without receiving any study drug.","numSubjects":"59"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"49"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"10"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"BG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"122"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.6","spread":"7.7"},{"groupId":"BG001","value":"58.9","spread":"7.2"},{"groupId":"BG002","value":"59.7","spread":"7.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"32"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"90"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"120"}]}]},{"title":"African","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"87"}]}]}]},{"title":"Curative Surgery Used","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Pneumonectomy","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"}]}]},{"title":"Lobectomy","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"92"}]}]},{"title":"Bi-lobectomy","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Smoking History","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"112"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"}]}]}]},{"title":"Stage of Disease Prior to Tumor Resection","description":"Classification based on the American Joint Committee on Cancer Staging Criteria for Lung Cancer.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage Ia","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Stage Ib","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"53"}]}]},{"title":"Stage IIa","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]},{"title":"Stage IIb","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"55"}]}]},{"title":"Stage IIIa","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Unknown: could have been either Stage IIIb or IV","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Tumor Type at Initial Pathological Diagnosis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma of the Lung","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"50"}]}]},{"title":"Squamous Carcinoma of the Lung","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"44"}]}]},{"title":"Non-Small Cell Lung Cancer","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}]}]},{"title":"Mixed Cell (Squamous/Adeno) Carcinoma of Lung","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"}]}]},{"title":"Large Cell Carcinoma of Lung","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"12"}]}]},{"title":"Bronchoalveolar Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"The Feasibility of Post-Surgery Chemotherapy","description":"Feasibility was measured by completion of 4 treatment cycles without remaining toxicities \\>=Grade 3 at 30 days after last infusion.","populationDescription":"Number of participants in safety population, that is, number of participants enrolled, randomized and treated with at least one dose of study drug (presented by treatment received arm).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"every 21-day cycle for 4 cycles up to 30 days after last infusion","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Participants \"feasible\"","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"27"}]}]},{"title":"Non-feasible = Early Discontinuation","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"}]}]},{"title":"Non-feasible = Lost to Follow-up","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Non-feasible = Remaining Grade 3/4 Toxicity","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Non-feasible = Underdosage (<95% intended dose)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"}]}]}],"analyses":[{"groupIds":["OG000"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Feasibility Response Rate (percentage)","paramValue":"59.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"46.4","ciUpperLimit":"71.5"},{"groupIds":["OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Feasibility Response Rate (percentage)","paramValue":"50.0","ciPctValue":"95","ciLowerLimit":"36.1","ciUpperLimit":"63.9"}]},{"type":"SECONDARY","title":"Grade III/IV Adverse Events","description":"Number of participants experiencing Grade III/IV hematologic and non-hematologic adverse events possibly related to study drug or protocol procedures in this study.","populationDescription":"Number of participants in safety population, that is, number of participants enrolled, randomized and treated with at least one dose of study drug (presented by treatment received arm).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"every 21-day cycle for 4 cycles","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"54"}]}],"classes":[{"title":"Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}]}]},{"title":"Anaemia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Thrombocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Febrile neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Leukopenia","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Lymphopenia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Neutrophil count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"Haemoglobin count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Platelet count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"White blood cell count decreased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Asthenia","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Catheter related infection","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Gamma-glutamyltransferase increased","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Anorexia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyperglycaemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyperkalaemia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Psychotic disorder","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival at 3 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year survival rate. Results are presented as probability (%) of survival at 3 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.","populationDescription":"All randomized participants. Intent to treat population.","reportingStatus":"POSTED","anticipatedPostingDate":"2011-12","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent probability of survival (%)","timeFrame":"baseline to date of death from any cause, assessed at 3 years","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","lowerLimit":"72.4","upperLimit":"91.6"},{"groupId":"OG001","value":"83.2","lowerLimit":"73.2","upperLimit":"93.2"}]}]}]},{"type":"SECONDARY","title":"3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 3 year disease-free rate. Disease-free survival is defined as the time from enrollment to the first observation of disease progression, or death due to any cause. For participants not known to have died and to have had recurrent disease, disease-free survival was censored at the date of the last participant contact with No Recurrence status. Results are presented as probability (%) of disease-free survival at 3 years.","populationDescription":"All randomized participants. Intent to Treat population.","reportingStatus":"POSTED","anticipatedPostingDate":"2011-12","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"probability of disease-free survival (%)","timeFrame":"length of time disease free, assessed at 3 years","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","lowerLimit":"48.3","upperLimit":"74.0"},{"groupId":"OG001","value":"67.3","lowerLimit":"54.5","upperLimit":"80.1"}]}]}]},{"type":"SECONDARY","title":"Overall Survival at 6 Years","description":"For each treatment arm, the Kaplan-Meier technique was used to estimate the 6 year survival rate. Results are presented as probability (%) of survival at 6 years. Overall survival is the duration from enrollment to death. For participants not known to have died, overall survival was censored at the last known alive date.","populationDescription":"All randomized participants. Intent to treat population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percent probability of survival (%)","timeFrame":"Baseline to date of death from any cause assessed at 6 years","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"59"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","lowerLimit":"59.3","upperLimit":"85.9"},{"groupId":"OG001","value":"83.2","lowerLimit":"73.2","upperLimit":"93.2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"baseline through four 21-day cycles and up to 30 days of follow-up after last infusion","eventGroups":[{"id":"EG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Cisplatin: 75 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles","seriousNumAffected":18,"seriousNumAtRisk":64,"otherNumAffected":61,"otherNumAtRisk":64},{"id":"EG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed: 500 mg/m\\^2, intravenous (IV), every 21 days x 4 cycles Carboplatin: area under the curve (AUC) 5 mg/ml\\*min, intravenous (IV), every 21 days x 4 cycles","seriousNumAffected":5,"seriousNumAtRisk":54,"otherNumAffected":52,"otherNumAtRisk":54}],"seriousEvents":[{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":54}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Visual disturbance","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Splenic artery aneurysm","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":54}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":54}]},{"term":"Catheter related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Restlessness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":54}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":54}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":64},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":54}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":54}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":21,"numAtRisk":64},{"groupId":"EG001","numEvents":36,"numAffected":15,"numAtRisk":54}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":12,"numAffected":7,"numAtRisk":54}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":54}]},{"term":"Keratoconjunctivitis sicca","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":54}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":17,"numAtRisk":64},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":54}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":64},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":54}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":54}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":40,"numAtRisk":64},{"groupId":"EG001","numEvents":60,"numAffected":30,"numAtRisk":54}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":54}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":21,"numAtRisk":64},{"groupId":"EG001","numEvents":24,"numAffected":17,"numAtRisk":54}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":54}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":54}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":23,"numAtRisk":64},{"groupId":"EG001","numEvents":25,"numAffected":21,"numAtRisk":54}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":54}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":54}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":54}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":64},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":54}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":11,"numAffected":6,"numAtRisk":54}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":22,"numAffected":10,"numAtRisk":54}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":16,"numAffected":10,"numAtRisk":54}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":17,"numAffected":9,"numAtRisk":54}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":10,"numAtRisk":64},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":54}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":54}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":54}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":64},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":54}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":54}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":54}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":64},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":54}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":64},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":54}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":54}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":64},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":54}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":64},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":54}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (10.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":64},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":54}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"A protocol amendment was approved after the trial original completed to allow for collection of additional overall survival data due to number of participants surviving at 3 years."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"1-800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}